Shenzhen Genoimmune Medical Institute (GIMI)

Revolutionizing Cancer Treatment with Advanced 4th Generation CAR-T Technology

The Shenzhen Geno-Immune Medical Institute (GIMI) stands at the forefront of gene and immune cell therapy, pioneering innovative solutions beyond FDA-approved CAR-T treatments. Led by renowned expert Prof. Lung-Ji Chang, inventor of the widely-adopted lentiviral vector system, GIMI has delivered effective treatments for over 1,000 cancer cases with cutting-edge 4th generation CAR-T technologies.

Key Facts:

• Founded: 2015
• Location: Shenzhen, China
• Facility: 4000 m² GMP-certified labs
• Specialties: CAR-T, TCR-T, gene therapy
• Clinical Trials: 30+ successful investigator-initiated and registered trials

Why Choose GIMI?

• Affordable Price: Treatments up to 50% cheaper than similar US or European CAR-T solutions (100k – 200k USD)
• Broader Cancer Coverage: Treats over 20 cancer types, including solid tumors not yet FDA-approved, such as hepatocellular carcinoma (HCC), gastric, ovarian, lung, pancreatic, and brain tumors.
• Rapid Treatment Availability: CAR-T preparation and patient infusion within 5-7 days.
• High Safety Profile: Incorporates innovative “suicide gene” safety switch technology to minimize side effects.

Advanced 4th Generation CAR-T Technology (4SCAR-T)

GIMI’s patented 4SCAR-T technology integrates enhanced cytokine signaling (CD27), immune memory improvement, and a built-in inducible Caspase-9 safety mechanism, offering superior efficacy and significantly reduced risk of severe side effects such as cytokine release syndrome (CRS) and neurotoxicity (ICANS).

Proven Clinical Outcomes

Acute Lymphoblastic Leukemia (ALL): 94% response rate, 80% complete remission.

Advanced Stage Lymphomas: Over 100 successful cases.

Solid Tumors: Effective CAR-T treatments for brain tumors (DIPG), gastric lymphoma (MALT), ovarian cancer, and hepatocellular carcinoma.

Leadership and Scientific Excellence

Prof. Lung-Ji Chang, President

• Experience: Tenured professor, University of Florida College of Medicine (1997–2020), former advisor to the U.S. FDA on cellular and gene therapies.
• Publications & Patents: Over 150 peer-reviewed articles, h-index 47; inventor of key patents including lentiviral vector systems and advanced CAR-T methods.
• Awards & Recognition: Class A Talent (Shenzhen Peacock Program), United Nations consultant, leading international authority in gene therapy.

Treatment Programs Available

Solid Tumor Solutions

• GPC3 CAR-T Therapy (Hepatocellular carcinoma)
• HER2 & Claudin 18.2 CAR-T Therapy (Gastric, ovarian, pancreatic cancers)
• GD2/PSMA CAR-T Therapy (Glioma, DIPG brain tumors)
• Universal CAR-NK Cell Therapy (Off-the-shelf treatment)

Hematological Malignancies

1. CD19/CD22 CAR-T Therapy (ALL, lymphoma, Burkitt’s lymphoma)
2. BCMA CAR-T Therapy (Multiple Myeloma)

Comparison to FDA-Approved Treatments

International Patient Services

ELT and GIMI ensure a seamless patient experience by providing:

• Comprehensive visa support
• Professional interpreter services (English, Russian, Arabic)
• Dedicated patient concierge for travel arrangements
• Comfortable accommodations and transport logistics
• Ongoing remote monitoring and follow-up

Getting Started – Simple 3-Step Process

1. Upload Medical Records: Receive tumor board review within 48 hours.
2. Receive Personalized Treatment Plan: Detailed proposal with transparent pricing.
3. Travel & Treatment: Personalized care and seamless logistics coordinated by GIMI’s dedicated international relations team.